These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24952230)

  • 1. The integrity of the cholinergic system determines memory performance in healthy elderly.
    Richter N; Allendorf I; Onur OA; Kracht L; Dietlein M; Tittgemeyer M; Neumaier B; Fink GR; Kukolja J
    Neuroimage; 2014 Oct; 100():481-8. PubMed ID: 24952230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
    Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter lesions and the cholinergic deficit in aging and mild cognitive impairment.
    Richter N; Michel A; Onur OA; Kracht L; Dietlein M; Tittgemeyer M; Neumaier B; Fink GR; Kukolja J
    Neurobiol Aging; 2017 May; 53():27-35. PubMed ID: 28208063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD.
    Richter N; Nellessen N; Dronse J; Dillen K; Jacobs HIL; Langen KJ; Dietlein M; Kracht L; Neumaier B; Fink GR; Kukolja J; Onur OA
    Neuroimage Clin; 2019; 24():101978. PubMed ID: 31422337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evaluation of N-[18F]fluoroethylpiperidin-4ylmethyl acetate in rats compared with MP4A as a probe for measuring cerebral acetylcholinesterase activity.
    Kikuchi T; Okamura T; Zhang MR; Fukushi K; Irie T
    Synapse; 2010 Mar; 64(3):209-15. PubMed ID: 19862687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis.
    Marcone A; Garibotto V; Moresco RM; Florea I; Panzacchi A; Carpinelli A; Virta JR; Tettamanti M; Borroni B; Padovani A; Bertoldo A; Herholz K; Rinne JO; Cappa SF; Perani D
    J Alzheimers Dis; 2012; 31(2):387-99. PubMed ID: 22596267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease.
    Bohnen NI; Kaufer DI; Hendrickson R; Ivanco LS; Lopresti B; Davis JG; Constantine G; Mathis CA; Moore RY; DeKosky ST
    Neurosci Lett; 2005 May 20-27; 380(1-2):127-32. PubMed ID: 15854764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease.
    Eggers C; Herholz K; Kalbe E; Heiss WD
    Neurosci Lett; 2006 Nov; 408(1):46-50. PubMed ID: 16996687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease.
    Tanaka N; Fukushi K; Shinotoh H; Nagatsuka S; Namba H; Iyo M; Aotsuka A; Ota T; Tanada S; Irie T
    J Cereb Blood Flow Metab; 2001 Mar; 21(3):295-306. PubMed ID: 11295884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age.
    Namba H; Iyo M; Fukushi K; Shinotoh H; Nagatsuka S; Suhara T; Sudo Y; Suzuki K; Irie T
    Eur J Nucl Med; 1999 Feb; 26(2):135-43. PubMed ID: 9933347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease.
    Iyo M; Namba H; Fukushi K; Shinotoh H; Nagatsuka S; Suhara T; Sudo Y; Suzuki K; Irie T
    Lancet; 1997 Jun; 349(9068):1805-9. PubMed ID: 9269216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease.
    Hirano S; Shinotoh H; Shimada H; Ota T; Sato K; Tanaka N; Zhang MR; Higuchi M; Fukushi K; Irie T; Kuwabara S; Suhara T
    J Alzheimers Dis; 2018; 62(4):1539-1548. PubMed ID: 29562505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.
    Nagatsuka Si S; Fukushi K; Shinotoh H; Namba H; Iyo M; Tanaka N; Aotsuka A; Ota T; Tanada S; Irie T
    J Cereb Blood Flow Metab; 2001 Nov; 21(11):1354-66. PubMed ID: 11702050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET.
    Shiraishi T; Kikuchi T; Fukushi K; Shinotoh H; Nagatsuka S; Tanaka N; Ota T; Sato K; Hirano S; Tanada S; Iyo M; Irie T
    Neuropsychopharmacology; 2005 Dec; 30(12):2154-61. PubMed ID: 15920507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease.
    Irie T; Fukushi K; Namba H; Iyo M; Tamagami H; Nagatsuka S; Ikota N
    J Nucl Med; 1996 Apr; 37(4):649-55. PubMed ID: 8691261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic system function and cognition in mild cognitive impairment.
    Haense C; Kalbe E; Herholz K; Hohmann C; Neumaier B; Krais R; Heiss WD
    Neurobiol Aging; 2012 May; 33(5):867-77. PubMed ID: 20961662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced acetylcholinesterase activity in the fusiform gyrus in adults with autism spectrum disorders.
    Suzuki K; Sugihara G; Ouchi Y; Nakamura K; Tsujii M; Futatsubashi M; Iwata Y; Tsuchiya KJ; Matsumoto K; Takebayashi K; Wakuda T; Yoshihara Y; Suda S; Kikuchi M; Takei N; Sugiyama T; Irie T; Mori N
    Arch Gen Psychiatry; 2011 Mar; 68(3):306-13. PubMed ID: 21383265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic activity correlates with reserve proxies in Alzheimer's disease.
    Garibotto V; Tettamanti M; Marcone A; Florea I; Panzacchi A; Moresco R; Virta JR; Rinne J; Cappa SF; Perani D
    Neurobiol Aging; 2013 Nov; 34(11):2694.e13-8. PubMed ID: 23820589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism.
    Herholz K; Bauer B; Wienhard K; Kracht L; Mielke R; Lenz MO; Strotmann T; Heiss WD
    J Neural Transm (Vienna); 2000; 107(12):1457-68. PubMed ID: 11458998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.